Equity intelligence report • May 13, 2026
In Q1 2026, AbbVie reported strong revenues of approximately $15 billion, despite a significant 40.3% decline from its leading product, Humira. The company's optimistic outlook is underscored by a commitment to invest $1.4 billion in a new North Carolina manufacturing facility, part of a broader $1.78 billion infrastructure investment plan. Analysts responded positively to AbbVie's performance, resulting in increased earnings guidance and stock upgrades. Meanwhile, the broader pharmaceutical sector faces intensifying competition, with Pfizer grappling with regulatory changes and aggressive rivals, contributing to market fluctuations that underscore the complexities of the current financial landscape.
Click a month on the chart to update the report below.
